Champions Oncology (CSBR) 10-Q 19 Mar 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Jan. 31, 2018	Mar. 16, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jan. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Entity Registrant Name	CHAMPIONS ONCOLOGY, INC.
Entity Central Index Key	771,856
Current Fiscal Year End Date	--04-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	CSBR
Entity Common Stock, Shares Outstanding		11,000,847

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jan. 31, 2018	Apr. 30, 2017
Current assets:
Cash and cash equivalents	$ 1,062	$ 3,295
Accounts receivable, net	2,942	2,274
Prepaid expenses and other current assets	185	300
Total current assets	4,189	5,869
Restricted cash	150	150
Property and equipment, net	1,980	1,216
Other Long Term Assets	107	107
Goodwill	669	669
Total assets	7,095	8,011
Current liabilities:
Accounts payable	1,961	1,852
Accrued liabilities	365	685
Deferred revenue	3,851	4,910
Total current liabilities	6,177	7,447
Other non-current liabilities	446	164
Total liabilities	6,623	7,611
Stockholders’ equity:
Common stock, $.001 par value; 200,000,000 shares authorized; 11,277,675 and 11,251,844 shares issued and 11,000,847 and 10,982,159 shares outstanding as of January 31, 2018 and April 30, 2017, respectively	11	11
Treasury stock, at cost, 269,685 common shares as of January 31, 2018 and April 30, 2017	(1,252)	(1,252)
Additional paid-in capital	71,906	70,991
Accumulated deficit	(70,193)	(69,350)
Total stockholders’ equity	472	400
Total liabilities and stockholders’ equity	$ 7,095	$ 8,011

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - $ / shares	Jan. 31, 2018	Apr. 30, 2017
Statement of Financial Position [Abstract]
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	11,277,675	11,251,844
Common Stock, shares outstanding	11,000,847	10,982,159
Treasury Stock, common shares	269,685	269,685

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2018	Jan. 31, 2017	Jan. 31, 2018	Jan. 31, 2017
Operating revenue:
Personalized oncology solutions	$ 259,000	$ 347,000	$ 1,077,000	$ 1,354,000
Translational oncology solutions	4,823,000	3,218,000	14,242,000	10,337,000
Total operating revenue	5,082,000	3,565,000	15,319,000	11,691,000
Costs and operating expenses:
Cost of personalized oncology solutions	220,000	320,000	871,000	1,167,000
Cost of translational oncology solutions	2,253,000	2,086,000	6,866,000	5,965,000
Research and development	1,045,000	998,000	3,308,000	3,217,000
Sales and marketing	627,000	726,000	1,862,000	2,369,000
General and administrative	1,004,000	836,000	3,167,000	3,393,000
Total costs and operating expenses	5,149,000	4,966,000	16,074,000	16,111,000
Loss from operations	(67,000)	(1,401,000)	(755,000)	(4,420,000)
Other (expense):
Other (expense)	(7,000)	(8,000)	(71,000)	(33,000)
Total other (expense)	(7,000)	(8,000)	(71,000)	(33,000)
Loss before provision for income taxes	(74,000)	(1,409,000)	(826,000)	(4,453,000)
Provision for income taxes	2,000	0	18,000	7,000
Net loss	$ (76,000)	$ (1,408,904)	$ (844,000)	$ (4,459,773)
Net loss per common share outstanding
Net loss per common share outstanding, basic and diluted (in dollars per share)	$ (0.01)	$ (0.13)	$ (0.08)	$ (0.44)
Weighted average common shares outstanding
Weighted average common shares outstanding, basic and diluted (in shares)	10,994,434	10,967,738	10,987,797	10,130,460

UNAUDITED CONDENSED CONSOLIDAT5

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Operating activities:
Net loss	$ (844,000)	$ (4,459,773)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	848,000	1,901,000
Depreciation expense	253,000	127,000
Issuance of common stock for services	15,000	20,000
Changes in operating assets and liabilities:
Accounts receivable	(669,000)	(714,000)
Prepaid expenses and other current assets	115,000	(98,000)
Accounts payable	124,000	(572,000)
Accrued liabilities	(320,000)	55,000
Other non-current liability	302,000	20,000
Deferred revenue	(1,059,000)	483,000
Net cash used in operating activities	(1,235,000)	(3,238,000)
Investing activities:
Purchase of property and equipment	(1,017,000)	(181,000)
Net cash used in investing activities	(1,017,000)	(181,000)
Financing activities:
Proceeds from June 2016 Public Offering, net of financing costs of $742	0	4,340,000
Proceeds from exercise of options	38,000	0
Capital lease payments	(19,000)	(18,000)
Net cash provided by financing activities	19,000	4,322,000
(Decrease)/Increase in cash and cash equivalents.	(2,233,000)	903,000
Cash and cash equivalents, beginning of period	3,295,000	2,585,000
Cash and cash equivalents, end of period	$ 1,062,000	$ 3,488,000

UNAUDITED CONDENSED CONSOLIDAT6

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICAL) $ in Thousands	9 Months Ended
	Jan. 31, 2017USD ($)
Statement of Cash Flows [Abstract]
Payments of financing costs	$ 742

Organization, Use of Estimates

Organization, Use of Estimates and Basis of Presentation	9 Months Ended
	Jan. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Use of Estimates and Basis of Presentation	Organization, Use of Estimates and Basis of Presentation Champions Oncology, Inc. (the “Company”) is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Personalized Oncology Solutions (“POS”) and Translational Oncology Solutions (“TOS”). POS assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings. The Company has two operating subsidiaries: Champions Oncology (Israel), Limited and Champions Biotechnology U.K., Limited. For the three and nine months ended January 31, 2018 and 2017 , there were no revenues earned by these subsidiaries. The Company’s foreign subsidiaries functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations. These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. All significant intercompany transactions and accounts have been eliminated. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, or GAAP, has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended April 30, 2017 , as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Annual Report on Form 10-K for the year ended April 30, 2017 . The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Liquidity Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and strategic initiatives. In the past, we have met these cash requirements through our sales of products and services, working capital management, and proceeds from certain private and public offerings of our securities. For the nine months ended January 31, 2018 , we had a net loss of $844,000 and net operating cash outflows of $1.2 million . In addition, as of January 31, 2018 , we had negative working capital of $2.0 million and cash and cash equivalents on hand of $1.1 million . The reduction of cash from year-end was mainly due to the $910,000 investment in equipment for our new lab facility along with the realization of deferred revenue, timing of accounts receivable collections and expense payments in the normal course of business. Additionally, we incurred approximately $100,000 of non-capitalized, non-recurring costs related to the new lab set-up. Finally, we closed on a line of credit ("LOC") agreement which provides that the Company may borrow up to $1.5 million. The Company does not plan to utilize the LOC as we believe that our cash and cash equivalents on hand at January 31, 2018 and future revenues are adequate to fund our operations through at least March 2019. However, in order for us to continue our operations beyond March 2019, we need to continue to increase revenues while managing increases in expense levels. If we are unable to maintain our operating levels, we may need to obtain capital from external sources. If we could not obtain additional financing, we may be required to reduce the scope of, or delay or eliminate, some of our research and development and other activities, which could harm our financial condition and operating results. Financing may not be available on acceptable terms or at all, and our failure to raise capital when needed could negatively impact our growth plans and our financial condition and results of operations. Additional equity financing may be dilutive to the holders of our common stock and debt financing, if available, may involve significant cash payment obligations and covenants and/or financial ratios that could restrict our ability to operate our business. Earnings Per Share Basic net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock plus dilutive potential common stock considered outstanding during the period. Such dilutive shares consist of incremental shares that would be issued upon exercise of the Company’s common stock purchase warrants and stock options. For the three and nine months ended January 31, 2018 and 2017 , basic and dilutive loss per share were the same, as the potentially dilutive securities did not have a dilutive effect. Three Months Ended Nine Months Ended 2018 2017 2018 2017 Basic and diluted net loss per share computation: Net loss attributable to common stockholders $ (75,359 ) $ (1,408,904 ) $ (843,094 ) $ (4,459,773 ) Weighted Average common shares – basic 10,994,434 10,967,738 10,987,797 10,130,460 Basic and diluted net loss per share $ (0.01 ) $ (0.13 ) $ (0.08 ) $ (0.44 ) The following table reflects the total potential share-based instruments outstanding at January 31, 2018 and 2017 that could have an effect on the future computation of dilution per common share: January 31, 2018 2017 Stock options 2,518,845 2,308,704 Warrants 2,004,284 2,109,840 Total common stock equivalents 4,523,129 4,418,544 Income Taxes Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements. In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient operating history, a valuation allowance is established. The Company adjusts the valuation allowance in the period management determines it is more likely than not that net deferred tax assets will or will not be realized. Changes in valuation allowances from period to period are included in the tax provision in the period of change. As of January 31, 2018 and April 30, 2017 , the Company provided a valuation allowance for all net deferred tax assets, as recovery is more likely than not based on an insufficient history of earnings. Tax positions are positions taken in a previously filed tax return or positions expected to be taken in a future tax return that are reflected in measuring current or deferred income tax assets and liabilities reported in the consolidated financial statements. Tax positions include, but are not limited to, the following: • An allocation or shift of income between taxing jurisdictions; • The characterization of income or a decision to exclude reportable taxable income in a tax return; or • A decision to classify a transaction, entity or other position in a tax return as tax exempt. The Company reflects tax benefits only if it is more likely than not that we will be able to sustain the tax position, based on its technical merits. If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized. The Company has recorded $121,000 of liabilities related to uncertain tax positions relative to one of its foreign operations as of January 31, 2018 and April 30, 2017 . The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company’s balance sheets at January 31, 2018 and April 30, 2017 , and has not recognized interest and/or penalties in the statement of operations for either period. We do not anticipate any significant unrecognized tax benefits will be recorded during the next 12 months. The income tax provision for the nine months ended January 31, 2018 and 2017 was $18,000 and $7,000 , respectively. On December 22, 2017, the Tax Cuts and Jobs Act (the “Act”) was signed into law. Among other provisions, the Act reduced the federal statutory corporate income tax rate from 35% to 21%, limited the deduction of net operating losses generated in tax years beginning after December 31, 2017 to 80% of taxable income, provided for indefinite carryforward of net operating losses generated in tax years after 2018 and elimination of net operating loss carrybacks, changes the treatment of offshore earnings regardless of whether they are repatriated and provides for the current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations. We measure our deferred tax assets and liabilities using the enacted tax rates that we believe will apply in the years in which the temporary differences are expected to be recovered or paid. As of January 31, 2018 , we have made a reasonable estimate of the effects of the Tax Act on our existing deferred taxes and related disclosures by reducing our net federal and state deferred tax assets by $7 million for the reduction in corporate tax rate. This adjustment to our deferred tax assets is offset against the valuation allowance. Additionally, the SEC staff has issued SAB 118, which allows the Company to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. Because the Company is still in the process of analyzing certain provisions of the Tax Act, the Company has determined that the adjustment to its deferred taxes was a provisional amount as permitted under SAB 118.

Property and Equipment

Property and Equipment	9 Months Ended
	Jan. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment is recorded at cost and primarily consists of laboratory equipment, leasehold improvements, furniture and fixtures, and computer equipment and software. Depreciation and amortization is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following (table in thousands): January 31, April 30, (unaudited) Furniture and fixtures $ 73 $ 74 Computer equipment and software 961 872 Laboratory equipment 2,255 918 Assets in progress 50 472 Leasehold improvements — 2 Total property and equipment 3,339 2,338 Less: Accumulated depreciation (1,359 ) (1,122 ) Property and equipment, net $ 1,980 $ 1,216 Depreciation and amortization expense, excluding expense recorded under capital lease, was $98,000 and $34,000 for the three months ended January 31, 2018 and 2017 , respectively, and $233,000 and $108,000 for the nine months ended January 31, 2018 and 2017 , respectively. As of January 31, 2018 and April 30, 2017 , property, plant and equipment included assets held under capital lease of $130,000 and $ 124,000 , respectively. Related depreciation expense was $7,000 and $6,000 , respectively, for the three months ended January 31, 2018 and 2017 , and $20,000 and $19,000 for the nine months ended January 31, 2018 and 2017 , respectively. Capital Lease In November 2014, the Company entered into a capital lease for laboratory equipment. The lease has costs of approximately $149,000 and matures on November 2019. The current monthly capital lease payment is approximately $3,000 . The following is a schedule by years of future minimum lease payments under this capital lease together with the present value of the net minimum lease payments as of January 31, 2018 (table in thousands): For the Years Ended April 30, Total 2018 (remaining) $ 8 2019 28 2020 16 Total minimum payments 52 Less: amount representing interest (3 ) Present value of minimum payments 49 Less: current portion (26 ) $ 23 The present value of minimum future obligations shown above is calculated based on an interest rate of 5% . The short-term and long-term components of the capital lease obligation are included in accrued liabilities and other non-current liabilities, respectively at January 31, 2018 and April 30, 2017 .

Share-Based Payments

Share-Based Payments	9 Months Ended
	Jan. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Payments	Share-Based Payments The Company has in place a 2010 Equity Incentive Plan and a 2008 Equity Incentive Plan. In general, these plans provide for stock-based compensation in the form of (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards. Stock-based compensation in the amount of $152,000 and $237,000 was recognized for the three months ended January 31, 2018 and 2017 , respectively, and $ 863,000 and $ 1.9 million was recognized for the nine months ended January 31, 2018 and 2017 , respectively. Included in stock-based compensation expense for the the nine months ended January 31, 2018 under general and administrative line item is an option modification charge of $56,529 and $ 15,000 related to the issuance of common stock as compensation for services performed. Stock-based compensation expense was recognized as follows (table in thousands): Three Months Ended Nine Months Ended 2018 2017 2018 2017 General and administrative $ 110 $ 184 $ 629 $ 1,482 Sales and marketing 7 7 47 194 Research and development 33 44 156 174 TOS cost of sales 2 2 30 49 POS cost of sales — — 1 2 Total stock-based compensation expense $ 152 $ 237 $ 863 $ 1,901 On January 31, 2018 , there was $203,420 in unrecognized stock based compensation which will be recognized as expense over 4.3 years. Stock Option Grants Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2018 and 2017 were as follows: Three Months Ended Nine Months Ended 2018 2017 2018 2017 Expected term in years 3 3 3 - 6 3 - 6 Risk-free interest rates 1.98% 0.59% - 1.90% 1.77% - 1.98% 0.59% - 1.90% Volatility 85.59% 72.12% - 87.96% 85.59% - 87.66% 72.12% - 87.96% Dividend yield —% —% —% —% The weighted average fair value of stock options granted during the three months ended January 31, 2018 and 2017 was $2.32 and $1.35 , respectively, and $1.95 and $1.71 was recognized for the nine months ended January 31, 2018 and 2017 , respectively. The Company’s stock options activity for the nine months ended January 31, 2018 was as follows: Non- Employees Directors and Employees Total Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, May 1, 2017 50,000 2,258,704 2,308,704 $ 2.86 6.1 $ 1,282,000 Granted — 267,310 267,310 2.68 Exercised — (12,500 ) (12,500 ) 3.00 Forfeited — (6,042 ) (6,042 ) 7.58 Canceled — — — — Expired — (38,627 ) (38,627 ) 5.21 Outstanding, January 31, 2018 50,000 2,468,845 2,518,845 2.80 5.8 $ 3,921,000 Vested and expected to vest as of January 31, 2018 50,000 2,468,845 2,518,845 2.80 5.8 $ 3,921,000 Exercisable as of January 31, 2018 25,836 2,389,471 2,415,307 2.77 5.7 $ 3,847,000 Stock Purchase Warrants As of January 31, 2018 and April 30, 2017 , the Company had warrants outstanding for the purchase of 2,004,284 shares of its common stock, all of which were exercisable. Activity related to these warrants, which expire at various dates through March 2020, is summarized as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, May 1, 2017 2,004,284 $ 5.57 2.8 $ — Granted — — — — Exercised — — — — Expired — — — — Outstanding, January 31, 2018 2,004,284 $ 5.57 2.3 $ —

Related Party Transactions

Related Party Transactions	9 Months Ended
	Jan. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Related party transactions include transactions between the Company and its shareholders, management, or affiliates. The following transactions were in the normal course of operations and were measured and recorded at the exchange amount, which is the amount of consideration established and agreed to by the parties. Consulting Services During the nine months ended January 31, 2018 and 2017 , the Company paid a member of its Board of Directors $54,000 and $54,000 , respectively, for consulting services unrelated to his duties as a board member. During the nine months ended January 31, 2018 and 2017 , the Company paid an affiliate of a board member $ 73,000 and $22,000 , respectively, for consulting services unrelated to their duties as board members. As of January 31, 2018 , no amounts were due to these related parties.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jan. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases The Company currently leases its office facilities. Rent expenses totaled $480,000 and $297,000 for the nine months ended January 31, 2018 and 2017 , respectively. The Company considers its facilities adequate for our current operational needs. The Company leases the following facilities under non-cancelable operating lease agreements: • One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in November 2021 . The Company recognized $67,000 and $64,000 of rental costs relative to this lease for the nine months ended January 31, 2018 and 2017 , respectively. • 855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of laboratories and office space where the Company conducted operations related to its primary service offerings. This lease was terminated in October 2017 . The Company transitioned its activities from this location to the new location in Rockville, MD. The Company recognized $59,000 and $78,000 of rental costs relative to this lease for the nine months ended January 31, 2018 and 2017 , respectively. • 450 East 29t h Street, New York, New York, 10016, which is a laboratory facility. The Company recognized $52,000 and $155,000 of rental expense for the nine months ended January 31, 2018 and 2017 , respectively. The lease expired in May 2017 and was not renewed. • 1330 Piccard Drive, Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The Company executed this lease on January 11, 2017. The operating commencement date was August 11, 2017. This lease expires in August 2028 . The Company recognized $302,000 and nil of rental expense for the nine months ended January 31, 2018 and 2017 , respectively. Legal Matters The Company is not currently party to any legal matters to its knowledge. The Company is not aware of any other matters that would have a material impact on the Company’s financial position or results of operations. Registration Payment Arrangements The Company has entered into an Amended and Restated Registration Rights Agreement in connection with the March 2015 Private Placement and is discussed more fully in Note 7 in the Company’s Form 10-K for the fiscal year ended April 30, 2017 . This Amended and Restated Registration Rights Agreement contains provisions that may call for the Company to pay penalties in certain circumstances. This registration payment arrangement primarily relates to the Company’s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period. The Company has not accrued any liquidated damages associated with the Amended and Restated Registration Right Agreement as the Company has filed the required registration statement and anticipates continued compliance with the agreement.

Segment Information

Segment Information	9 Months Ended
	Jan. 31, 2018
Segment Reporting [Abstract]
Segment Information	Segment Information The Company operates in two reportable segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2 of the Company’s annual financial statements for the year ended April 30, 2017 , as filed on Form 10-K. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands): Three Months Ended January 31, 2018 Personalized Oncology Solutions (POS) Translational Oncology Solutions (TOS) Unallocated Corporate Overhead Consolidated Net revenue $ 259 $ 4,823 $ — $ 5,082 Direct cost of services (220 ) (2,251 ) — (2,471 ) Sales and marketing costs (94 ) (526 ) — (620 ) Other operating expenses — (1,013 ) (893 ) (1,906 ) Stock- based compensation expense (1) — — (152 ) (152 ) Segment profit (loss) $ (55 ) $ 1,033 $ (1,045 ) $ (67 ) Three Months Ended January 31, 2017 Personalized Oncology Solutions (POS) Translational Oncology Solutions (TOS) Unallocated Corporate Overhead Consolidated Net revenue $ 347 $ 3,218 $ — $ 3,565 Direct cost of services (320 ) (2,084 ) — (2,404 ) Sales and marketing costs (128 ) (591 ) — (719 ) Other operating expenses — (953 ) (653 ) (1,606 ) Stock- based compensation expense (1) — — (237 ) (237 ) Segment profit (loss) $ (101 ) $ (410 ) $ (890 ) $ (1,401 ) Nine Months Ended January 31, 2018 Personalized Translational Unallocated Consolidated Net revenue $ 1,077 $ 14,242 $ — $ 15,319 Direct cost of services (870 ) (6,836 ) — (7,706 ) Sales and marketing costs (265 ) (1,550 ) — (1,815 ) Other operating expenses — (3,152 ) (2,538 ) (5,690 ) Stock- based compensation expense (1) — — (863 ) (863 ) Segment profit (loss) $ (58 ) $ 2,704 $ (3,401 ) $ (755 ) Nine Months Ended January 31, 2017 Personalized Translational Unallocated Consolidated Net revenue $ 1,354 $ 10,337 $ — $ 11,691 Direct cost of services (1,165 ) (5,916 ) — (7,081 ) Sales and marketing costs (397 ) (1,778 ) — (2,175 ) Other operating expenses — (3,043 ) (1,911 ) (4,954 ) Stock- based compensation expense (1) — — (1,901 ) (1,901 ) Segment profit (loss) $ (208 ) $ (400 ) $ (3,812 ) $ (4,420 ) (1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments. See Note 3 for the allocation of stock compensation expense relative to the individual line items as it is reported on the Company's Consolidated Statements of Operations. All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.

Lines of Credit

Lines of Credit	9 Months Ended
	Jan. 31, 2018
Debt Disclosure [Abstract]
Lines of Credit	Lines of Credit On October 30, 2017, the Company entered into a line of credit agreement with a national bank which provides that the Company may borrow up to $1.5 million. Borrowings under the line bear interest payable monthly at the Wall Street Journal Prime Rate plus 1.5% to 2.0% and are secured by all assets of the Company. The balances payable under this arrangement are due on demand. As of January 31, 2018 , there were no outstanding borrowings. The revolving line maturity date is October 29, 2018.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Jan. 31, 2018
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP. In addition, this guidance requires new or expanded disclosures related to the judgments made by companies when following this framework and additional quantitative disclosures regarding contract balances and remaining performance obligations. On July 9, 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date. Early adoption of ASU 2014-09 is permitted but not before the original effective date (annual periods beginning after December 15, 2016). When effective, ASU 2014-09 prescribes either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company will adopt this guidance on May 1, 2018 . The Company is currently evaluating the overall impact that ASU 2014-09 will have on the Company’s consolidated financial statements, as well as the expected timing and method of adoption. The Company has established an implementation team, including external advisers, and has commenced the review of the Company’s revenue portfolio and related contracts across its various business units and geographies. Discussions regarding changes to the Company’s current accounting policies and practices remain ongoing and preliminary conclusions are subject to change. Upon adoption, the Company will recognize revenue from contracts with customers as each performance obligation is satisfied, either at a point in time or over a period of time, based on when control transfers to customers. The Company plans to adopt the new revenue recognition standard under the modified retrospective transition method by recognizing the cumulative effect of applying the standard as an adjustment to the Company’s Balance Sheet. Until the Company completes testing of the new revenue recognition standard, the Company does not anticipate being able to provide the impact of the new standard on the Balance Sheets or Statements of Operations however from the initial review and assessment of a sample of contracts with customers the Company does not anticipate the new accounting pronouncement to have a material impact on the Company’s financial statements, except enhanced disclosure regarding revenue recognition, including disclosures of revenue streams, performance obligations, variable consideration and the related judgments and estimates necessary to apply the new standard. In August 2014, the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The amendments in this update state that in connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016 and for annual periods and interim periods thereafter. Early application is permitted. The adoption of this update did not have a material impact on our consolidated financial statements. In February 2016, the FASB ASU No. 2016-02, Leases. The new standard will require most leases to be recognized on the balance sheet which will increase reported assets and liabilities. Lessor accounting remains substantially similar to current guidance. The new standard is effective for annual and interim periods in fiscal years beginning after December 15, 2018, which for us is the first quarter of fiscal 2019 and mandates a modified retrospective transition method. We are currently assessing the impact of this update on our consolidated financial statements. In April 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting”. The new standard simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU No. 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for financial statements that have not already been issued. The adoption of this update did not have a material impact on our consolidated financial statements. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. The new standard attempts to reduce diversity in practice in how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU No. 2016-15 provides guidance on eight specific cash flow issues. The new guidance will be effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years. Early adoption is permitted including adoption in an interim period. We do not intend to early adopt and we are currently assessing the impact of adoption of this update will have on our consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): “Simplifying the Test for Goodwill Impairment”. The update simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. It affects public entities that have goodwill reported in their financial statements and have not elected the private company alternative for the subsequent measurement of goodwill. A public entity that is a U.S. Securities and Exchange Commission ("SEC") filer should adopt the amendments in this update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. For the Company, the amendments are effective January 1, 2020. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.

Organization, Use of Estimate15

Organization, Use of Estimates and Basis of Presentation (Tables)	9 Months Ended
	Jan. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of the Calculation of Earnings per Share, Basic and Diluted	For the three and nine months ended January 31, 2018 and 2017 , basic and dilutive loss per share were the same, as the potentially dilutive securities did not have a dilutive effect. Three Months Ended Nine Months Ended 2018 2017 2018 2017 Basic and diluted net loss per share computation: Net loss attributable to common stockholders $ (75,359 ) $ (1,408,904 ) $ (843,094 ) $ (4,459,773 ) Weighted Average common shares – basic 10,994,434 10,967,738 10,987,797 10,130,460 Basic and diluted net loss per share $ (0.01 ) $ (0.13 ) $ (0.08 ) $ (0.44 )
Summary of Antidilutive Securities Excluded from Earnings Per Share Calculations	The following table reflects the total potential share-based instruments outstanding at January 31, 2018 and 2017 that could have an effect on the future computation of dilution per common share: January 31, 2018 2017 Stock options 2,518,845 2,308,704 Warrants 2,004,284 2,109,840 Total common stock equivalents 4,523,129 4,418,544

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Jan. 31, 2018
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consisted of the following (table in thousands): January 31, April 30, (unaudited) Furniture and fixtures $ 73 $ 74 Computer equipment and software 961 872 Laboratory equipment 2,255 918 Assets in progress 50 472 Leasehold improvements — 2 Total property and equipment 3,339 2,338 Less: Accumulated depreciation (1,359 ) (1,122 ) Property and equipment, net $ 1,980 $ 1,216
Schedule of Future Minimum Payment for Capital Leases	The following is a schedule by years of future minimum lease payments under this capital lease together with the present value of the net minimum lease payments as of January 31, 2018 (table in thousands): For the Years Ended April 30, Total 2018 (remaining) $ 8 2019 28 2020 16 Total minimum payments 52 Less: amount representing interest (3 ) Present value of minimum payments 49 Less: current portion (26 ) $ 23

Share-Based Payments (Tables)

Share-Based Payments (Tables)	9 Months Ended
	Jan. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Allocation of Share Based Compensation Expense	Stock-based compensation expense was recognized as follows (table in thousands): Three Months Ended Nine Months Ended 2018 2017 2018 2017 General and administrative $ 110 $ 184 $ 629 $ 1,482 Sales and marketing 7 7 47 194 Research and development 33 44 156 174 TOS cost of sales 2 2 30 49 POS cost of sales — — 1 2 Total stock-based compensation expense $ 152 $ 237 $ 863 $ 1,901
Valuation Assumptions for Stock Options	Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2018 and 2017 were as follows: Three Months Ended Nine Months Ended 2018 2017 2018 2017 Expected term in years 3 3 3 - 6 3 - 6 Risk-free interest rates 1.98% 0.59% - 1.90% 1.77% - 1.98% 0.59% - 1.90% Volatility 85.59% 72.12% - 87.96% 85.59% - 87.66% 72.12% - 87.96% Dividend yield —% —% —% —%
Summary of Stock Option Activity	The Company’s stock options activity for the nine months ended January 31, 2018 was as follows: Non- Employees Directors and Employees Total Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, May 1, 2017 50,000 2,258,704 2,308,704 $ 2.86 6.1 $ 1,282,000 Granted — 267,310 267,310 2.68 Exercised — (12,500 ) (12,500 ) 3.00 Forfeited — (6,042 ) (6,042 ) 7.58 Canceled — — — — Expired — (38,627 ) (38,627 ) 5.21 Outstanding, January 31, 2018 50,000 2,468,845 2,518,845 2.80 5.8 $ 3,921,000 Vested and expected to vest as of January 31, 2018 50,000 2,468,845 2,518,845 2.80 5.8 $ 3,921,000 Exercisable as of January 31, 2018 25,836 2,389,471 2,415,307 2.77 5.7 $ 3,847,000
Summary of Warrant Activity	Activity related to these warrants, which expire at various dates through March 2020, is summarized as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, May 1, 2017 2,004,284 $ 5.57 2.8 $ — Granted — — — — Exercised — — — — Expired — — — — Outstanding, January 31, 2018 2,004,284 $ 5.57 2.3 $ —

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Jan. 31, 2018
Segment Reporting [Abstract]
Summary of Segment Activity	The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands): Three Months Ended January 31, 2018 Personalized Oncology Solutions (POS) Translational Oncology Solutions (TOS) Unallocated Corporate Overhead Consolidated Net revenue $ 259 $ 4,823 $ — $ 5,082 Direct cost of services (220 ) (2,251 ) — (2,471 ) Sales and marketing costs (94 ) (526 ) — (620 ) Other operating expenses — (1,013 ) (893 ) (1,906 ) Stock- based compensation expense (1) — — (152 ) (152 ) Segment profit (loss) $ (55 ) $ 1,033 $ (1,045 ) $ (67 ) Three Months Ended January 31, 2017 Personalized Oncology Solutions (POS) Translational Oncology Solutions (TOS) Unallocated Corporate Overhead Consolidated Net revenue $ 347 $ 3,218 $ — $ 3,565 Direct cost of services (320 ) (2,084 ) — (2,404 ) Sales and marketing costs (128 ) (591 ) — (719 ) Other operating expenses — (953 ) (653 ) (1,606 ) Stock- based compensation expense (1) — — (237 ) (237 ) Segment profit (loss) $ (101 ) $ (410 ) $ (890 ) $ (1,401 ) Nine Months Ended January 31, 2018 Personalized Translational Unallocated Consolidated Net revenue $ 1,077 $ 14,242 $ — $ 15,319 Direct cost of services (870 ) (6,836 ) — (7,706 ) Sales and marketing costs (265 ) (1,550 ) — (1,815 ) Other operating expenses — (3,152 ) (2,538 ) (5,690 ) Stock- based compensation expense (1) — — (863 ) (863 ) Segment profit (loss) $ (58 ) $ 2,704 $ (3,401 ) $ (755 ) Nine Months Ended January 31, 2017 Personalized Translational Unallocated Consolidated Net revenue $ 1,354 $ 10,337 $ — $ 11,691 Direct cost of services (1,165 ) (5,916 ) — (7,081 ) Sales and marketing costs (397 ) (1,778 ) — (2,175 ) Other operating expenses — (3,043 ) (1,911 ) (4,954 ) Stock- based compensation expense (1) — — (1,901 ) (1,901 ) Segment profit (loss) $ (208 ) $ (400 ) $ (3,812 ) $ (4,420 ) (1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments. See Note 3 for the allocation of stock compensation expense relative to the individual line items as it is reported on the Company's Consolidated Statements of Operations.

Organization, Use of Estimate19

Organization, Use of Estimates and Basis of Presentation - Narrative (Details)	3 Months Ended		9 Months Ended
	Jan. 31, 2018USD ($)	Jan. 31, 2017USD ($)	Jan. 31, 2018USD ($)subsidiary	Jan. 31, 2017USD ($)	Oct. 30, 2017USD ($)	Apr. 30, 2017USD ($)	Apr. 30, 2016USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating subsidiaries | subsidiary			2
Net loss	$ (76,000)	$ (1,408,904)	$ (844,000)	$ (4,459,773)
Net cash used in operating activities			1,235,000	3,238,000
Positive working capital	2,000,000		2,000,000
Cash and cash equivalents	1,062,000	3,488,000	1,062,000	3,488,000		$ 3,295,000	$ 2,585,000
Investment in new lab equipment			910,000
Capitalized, non-recurring costs			100,000
Credit facility					$ 1,500,000
Unrecognized tax benefits	121,000		121,000			$ 121,000
Provision for income taxes	$ 2,000	$ 0	18,000	$ 7,000
Reduction of federal and state deferred tax assets			$ 7,000,000

Organization, Use of Estimate20

Organization, Use of Estimates and Basis of Presentation - Calculation of Earnings Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2018	Jan. 31, 2017	Jan. 31, 2018	Jan. 31, 2017
Basic loss per share computation
Net loss attributable to common stockholders	$ (76,000)	$ (1,408,904)	$ (844,000)	$ (4,459,773)
Weighted average common shares outstanding, basic (in shares)	10,994,434	10,967,738	10,987,797	10,130,460
Basic and diluted net loss per share (in dollars per share)	$ (0.01)	$ (0.13)	$ (0.08)	$ (0.44)

Organization, Use of Estimate21

Organization, Use of Estimates and Basis of Presentation - Summary of Potentially Antidilutive Securities (Details) - shares	9 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents	4,523,129	4,418,544
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents	2,518,845	2,308,704
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents	2,004,284	2,109,840

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Jan. 31, 2018	Apr. 30, 2017
Property, Plant and Equipment [Abstract]
Furniture and fixtures	$ 73	$ 74
Computer equipment and software	961	872
Laboratory equipment	2,255	918
Assets in progress	50	472
Leasehold improvements	0	2
Total property and equipment	3,339	2,338
Less: Accumulated depreciation	(1,359)	(1,122)
Property and equipment, net	$ 1,980	$ 1,216

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Nov. 30, 2014	Jan. 31, 2018	Jan. 31, 2017	Jan. 31, 2018	Jan. 31, 2017	Apr. 30, 2017
Property, Plant and Equipment [Line Items]
Depreciation		$ 98	$ 34	$ 233	$ 108
Capital leased assets, gross		$ 130		$ 130		$ 124
Capital leases monthly payments	$ 3
Capital leases of lessee, contingent rentals, basis spread on variable rate		5.00%		5.00%
Assets Held under Capital Leases
Property, Plant and Equipment [Line Items]
Depreciation		$ 7	$ 6	$ 20	$ 19
Equipment Leased to Other Party
Property, Plant and Equipment [Line Items]
Capital lease asset	$ 149
Minimum
Property, Plant and Equipment [Line Items]
Useful lives				3 years
Maximum
Property, Plant and Equipment [Line Items]
Useful lives				7 years

Property and Equipment - Schedu

Property and Equipment - Schedule of Future Minimum Payments for Capital Leases (Details) $ in Thousands	Jan. 31, 2018USD ($)
Property, Plant and Equipment [Abstract]
2018 (remaining)	$ 8
2,019	28
2,020	16
Total minimum payments	52
Less: amount representing interest	(3)
Present value of minimum payments	49
Less: current portion	(26)
Capital Lease, noncurrent	$ 23

Share-Based Payments - Allocati

Share-Based Payments - Allocation of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2018	Jan. 31, 2017	Jan. 31, 2018	Jan. 31, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 152	$ 237	$ 863	$ 1,901
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	110	184	629	1,482
Sales and marketing
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	7	7	47	194
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	33	44	156	174
TOS cost of sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	2	2	30	49
POS cost of sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 0	$ 0	$ 1	$ 2

Share-Based Payments - Valuatio

Share-Based Payments - Valuation Assumptions for Stock Options (Details)	3 Months Ended		9 Months Ended
	Jan. 31, 2018	Jan. 31, 2017	Jan. 31, 2018	Jan. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term in years	3 years
Risk-free interest rates	1.98%
Risk-free interest rates maximum		0.00%	1.98%	1.90%
Risk-free interest rates minimum		0.59%	1.77%	0.59%
Volatility	85.59%
Volatility maximum		87.96%	87.66%	87.96%
Volatility minimum		72.12%	85.59%	72.12%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term in years			3 years	3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term in years		3 years	6 years	6 years

Share-Based Payments - Summary

Share-Based Payments - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Jan. 31, 2018	Apr. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Shares, Outstanding, Beginning Balance	2,308,704
Shares, Granted	267,310
Shares, Exercised	(12,500)
Shares, Forfeited	(6,042)
Shares, Canceled	0
Shares, Expired	(38,627)
Shares, Outstanding, Ending Balance	2,518,845	2,308,704
Shares, Vested and expected to vest	2,518,845
Shares, Exercisable	2,415,307
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price, Outstanding, Beginning Balance (in usd per share)	$ 2.86
Weighted Average Exercise Price, Granted (in usd per share)	2.68
Weighted Average Exercise Price, Exercised (in usd per share)	3
Weighted Average Exercise Price, Forfeited (in usd per share)	7.58
Weighted Average Exercise Price, Canceled (in usd per share)	0
Weighted Average Exercise Price, Expired (in usd per share)	5.21
Weighted Average Exercise Price, Outstanding, Ending Balance (in usd per share)	2.80	$ 2.86
Weighted Average Exercise Price, Vested and expected to vest (in usd per share)	2.80
Weighted Average Exercise Price, Exercisable (in usd per share)	$ 2.77
Weighted Average Remaining Contractual Term, Outstanding, Beginning Balance (in years)		6 years 1 month 6 days
Weighted Average Remaining Contractual Life, Granted (in years)
Weighted Average Remaining Contractual Term, Outstanding, Ending Balance (in years)	5 years 9 months 18 days
Weighted Average Remaining Contractual Life, Vested and expected to vest (in years)	5 years 9 months 18 days
Weighted Average Remaining Contractual Life, Exercisable (in years)	5 years 8 months 12 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance	$ 1,282
Aggregate Intrinsic Value, Granted
Aggregate Intrinsic Value, Outstanding, Ending Balance	3,921	$ 1,282
Aggregate Intrinsic Value, Vested and expected to vest	3,921
Aggregate Intrinsic Value, Exercisable	$ 3,847
Non-employees
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Shares, Outstanding, Beginning Balance	50,000
Shares, Granted	0
Shares, Exercised	0
Shares, Forfeited	0
Shares, Canceled	0
Shares, Expired	0
Shares, Outstanding, Ending Balance	50,000	50,000
Shares, Vested and expected to vest	50,000
Shares, Exercisable	25,836
Directors and employees
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Shares, Outstanding, Beginning Balance	2,258,704
Shares, Granted	267,310
Shares, Exercised	(12,500)
Shares, Forfeited	(6,042)
Shares, Canceled	0
Shares, Expired	(38,627)
Shares, Outstanding, Ending Balance	2,468,845	2,258,704
Shares, Vested and expected to vest	2,468,845
Shares, Exercisable	2,389,471

Share-Based Payments - Summar28

Share-Based Payments - Summary of Warrant Activity (Details) - Warrants - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Jan. 31, 2018	Apr. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of Shares, Beginning Balance	2,004,284
Number of Shares, Granted	0
Number of Shares, Exercised	0
Number of Shares, Expired	0
Number of Shares, Ending Balance	2,004,284	2,004,284
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Exercise Price, Beginning Balance (in usd per share)	$ 5.57
Weighted Average Exercise Price, Granted (in usd per share)	0
Weighted Average Exercise Price, Exercised (in usd per share)	0
Weighted Average Exercise Price, Expired (in usd per share)	0
Weighted Average Exercise Price, Ending Balance (in usd per share)	$ 5.57	$ 5.57
Weighted Average Remaining Contractual Life (in years)	2 years 3 months 3 days	2 years 9 months 6 days
Aggregate Intrinsic Value, Beginning Balance	$ 0
Aggregate Intrinsic Value, Ending Balance	$ 0	$ 0

Share-Based Payments - Narrativ

Share-Based Payments - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2018	Jan. 31, 2017	Jan. 31, 2018	Jan. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 152,000	$ 237,000	$ 863,000	$ 1,901,000
Option modification charge			56,529
Shares issued in relation to consulting services, value			15,000
Issuance of common stock for services			15,000	$ 20,000
Unrecognized compensation cost	$ 203,420		$ 203,420
Period for recognition			4 years 3 months 19 days
Weighted-average grant date fair value (in usd per share)	$ 2.32	$ 1.35	$ 1.95	$ 1.71
Shares granted (in shares)			267,310
Grants in period, weighted average exercise price (in usd per share)			$ 2.68
Warrants outstanding (in shares)	2,004,284		2,004,284

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - USD ($)	9 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Board of directors chairman
Related Party Transaction [Line Items]
Related related party transaction, amounts of transaction	$ 54,000	$ 54,000
Substantial stockholders
Related Party Transaction [Line Items]
Related related party transaction, amounts of transaction	$ 73,000	$ 22,000

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) - USD ($)	9 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Commitments and Contingencies [Line Items]
Operating leases, rent expense	$ 480,000	$ 297,000
Corporate headquarters
Commitments and Contingencies [Line Items]
Operating leases, rent expense	$ 67,000	64,000
Lease expiration date	Nov. 30, 2021
Laboratories and office space
Commitments and Contingencies [Line Items]
Operating leases, rent expense	$ 59,000	78,000
Lease expiration date	Oct. 1, 2017
New York laboratory
Commitments and Contingencies [Line Items]
Operating leases, rent expense	$ 52,000	155,000
Lease expiration date	May 30, 2017
Rockville, MD
Commitments and Contingencies [Line Items]
Operating leases, rent expense	$ 302,000	$ 0

Segment Information - Summary o

Segment Information - Summary of Segment Activity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2018	Jan. 31, 2017	Jan. 31, 2018	Jan. 31, 2017
Segment Reporting Information [Line Items]
Net revenue	$ 5,082	$ 3,565	$ 15,319	$ 11,691
Sales and marketing costs	(627)	(726)	(1,862)	(2,369)
Stock- based compensation expense	(152)	(237)	(863)	(1,901)
Consolidated
Segment Reporting Information [Line Items]
Net revenue	5,082	3,565	15,319	11,691
Direct cost of services	(2,471)	(2,404)	(7,706)	(7,081)
Sales and marketing costs	(620)	(719)	(1,815)	(2,175)
Other operating expenses	(1,906)	(1,606)	(5,690)	(4,954)
Stock- based compensation expense	(152)	(237)	(863)	(1,901)
Segment profit (loss)	(67)	(1,401)	(755)	(4,420)
Operating Segments | Personalized Oncology Solutions (POS)
Segment Reporting Information [Line Items]
Net revenue	259	347	1,077	1,354
Direct cost of services	(220)	(320)	(870)	(1,165)
Sales and marketing costs	(94)	(128)	(265)	(397)
Other operating expenses	0	0	0	0
Stock- based compensation expense	0	0	0	0
Segment profit (loss)	(55)	(101)	(58)	(208)
Operating Segments | Translational Oncology Solutions (TOS)
Segment Reporting Information [Line Items]
Net revenue	4,823	3,218	14,242	10,337
Direct cost of services	(2,251)	(2,084)	(6,836)	(5,916)
Sales and marketing costs	(526)	(591)	(1,550)	(1,778)
Other operating expenses	(1,013)	(953)	(3,152)	(3,043)
Stock- based compensation expense	0	0	0	0
Segment profit (loss)	1,033	(410)	2,704	(400)
Unallocated Corporate Overhead
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Direct cost of services	0	0	0	0
Sales and marketing costs	0	0	0	0
Other operating expenses	(893)	(653)	(2,538)	(1,911)
Stock- based compensation expense	(152)	(237)	(863)	(1,901)
Segment profit (loss)	$ (1,045)	$ (890)	$ (3,401)	$ (3,812)

Lines of Credit - Narrative (De

Lines of Credit - Narrative (Details) - USD ($)	9 Months Ended
	Jan. 31, 2018	Oct. 30, 2017
Line of Credit Facility [Line Items]
Credit facility		$ 1,500,000
Minimum | Wall Street Journal Prime Rate
Line of Credit Facility [Line Items]
Spread on variable rate	1.50%
Maximum | Wall Street Journal Prime Rate
Line of Credit Facility [Line Items]
Spread on variable rate	2.00%